Access to anti-retroviral drugs, female in Chile

Chile: Access to anti-retroviral drugs, female was 63.0% in 2024. ▲ Rising

Latest (2024)
63.0%
Change on year
down 3.1%
World rank
96th
of 141 countries
All-time high
68.0%
in 2019
All-time low
11.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Chile, 2000–2024

2040602000201220242000: 11 %2001: 14 %2002: 20 %2003: 25 %2004: 26 %2005: 36 %2006: 39 %2007: 41 %2008: 41 %2009: 44 %2010: 46 %2011: 47 %2012: 49 %2013: 54 %2014: 57 %2015: 60 %2016: 57 %2017: 61 %2018: 65 %2019: 68 %2020: 68 %2021: 66 %2022: 66 %2023: 65 %2024: 63 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Chile is 63.0%, measured in 2024.

The figure is down 3.1% on the previous year and up 10.5% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Chile peaked at 68.0% in 2019 and was at its lowest, 11.0%, in 2000.

Chile ranks 96th of 141 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, female in Chile, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Chile, 2000 to 2024.
Year % Change
2000 11.0%
2001 14.0% +27.3%
2002 20.0% +42.9%
2003 25.0% +25.0%
2004 26.0% +4.0%
2005 36.0% +38.5%
2006 39.0% +8.3%
2007 41.0% +5.1%
2008 41.0% +0.0%
2009 44.0% +7.3%
2010 46.0% +4.5%
2011 47.0% +2.2%
2012 49.0% +4.3%
2013 54.0% +10.2%
2014 57.0% +5.6%
2015 60.0% +5.3%
2016 57.0% -5.0%
2017 61.0% +7.0%
2018 65.0% +6.6%
2019 68.0% +4.6%
2020 68.0% +0.0%
2021 66.0% -2.9%
2022 66.0% +0.0%
2023 65.0% -1.5%
2024 63.0% -3.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 29.7% 11.0% 44.0% 10
2010s 56.4% 46.0% 68.0% 10
2020s 65.6% 63.0% 68.0% 5

Countries ranked near Chile

  1. 95 Albania 64.0% compare
  2. 96 Gabon 63.0% compare
  3. 96 Slovakia 63.0% compare
  4. 99 Bolivia, Plurinational State of 62.0% compare
  5. 99 Jamaica 62.0% compare
  6. 99 Republic of Moldova 62.0% compare
  7. 99 Suriname 62.0% compare

See the full ranking of 160 places →

More gender data for Chile

All data for Chile →

Frequently asked questions

What is access to anti-retroviral drugs, female in Chile?
Access to anti-retroviral drugs, female in Chile was 63.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Chile?
The highest recorded value was 68.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Chile?
The lowest recorded value was 11.0% in 2000.
How does Chile rank for access to anti-retroviral drugs, female?
Chile ranks 96th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Chile?
Over the last ten years it is up 10.5%. The long-run trend across the full record is rising.
Where does this Chile data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Chile. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/chile/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/chile/">Access to anti-retroviral drugs, female in Chile</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.